Literature DB >> 33953374

Use of teprotumumab in thyroid eye disease.

Claire Greenhill1.   

Abstract

Entities:  

Year:  2021        PMID： 33953374     DOI： 10.1038/s41574-021-00505-1

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.

Authors:  George J Kahaly; Raymond S Douglas; Robert J Holt; Saba Sile; Terry J Smith
Journal:  Lancet Diabetes Endocrinol       Date:  2021-04-15       Impact factor: 32.069
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.